E-cigarette Cessation in Adults Who Co-use Cannabis

PHASE4RecruitingINTERVENTIONAL
Enrollment

105

Participants

Timeline

Start Date

February 19, 2025

Primary Completion Date

June 1, 2026

Study Completion Date

September 1, 2026

Conditions
Nicotine DependenceTobacco Use Disorder
Interventions
DRUG

Varenicline Pill

In this study, all participants will be administered active medication for a 12 week treatment period. The standard dose titration schedule will be used, which includes 0.5 mg once per day (q.d.) on Days 1-3, 0.5 mg twice per day (b.i.d.) on Days 4-7, and 1.0 mg b.i.d. starting on Day 8. Dosing of 2.0 mg per day will be maintained for the next 11 weeks, for a total of 12 weeks of active treatment for all study participants.

BEHAVIORAL

Contingency management

Contingency management procedures will be implemented and financial incentives will be provided at weekly visits contingent on e-cigarette abstinence verified through urinary qualitative cotinine (starting at Week 2). A set amount of $20 per study visit will be delivered based on a negative qualitative urinary cotinine result.

BEHAVIORAL

Counseling

Psychosocial counseling will be administered by trained research staff leading up to the target quit date and throughout the study.

Trial Locations (3)

29425

RECRUITING

MUSC Charleston, Charleston

29671

RECRUITING

Behavioral Health Services of Pickens County, Pickens

29720

RECRUITING

MUSC Lancaster, Lancaster

All Listed Sponsors
collaborator

National Cancer Institute (NCI)

NIH

lead

Medical University of South Carolina

OTHER